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Improved outcomes are associated with multilevel
endovascular intervention involving the tibial
vessels compared with isolated tibial intervention
Mikel Sadek, MD,a Sharif H. Ellozy, MD,b Irene C. Turnbull, MD,b Robert A. Lookstein, MD,b
Michael L. Marin, MD,b and Peter L. Faries, MD,b New York, NY
Objective: Endovascular intervention is increasingly accepted as an alternative to surgery for the treatment of tibial vessel
disease. Tibial vessel disease can occur in isolation or in conjunction with disease that involves the proximal lower
extremity vasculature (multilevel disease). This study evaluated the overall efficacy of endovascular intervention for tibial
vessel disease and whether the requirement for single-level compared with multilevel intervention affected outcomes.
Methods: This study evaluated a consecutive unselected group of patients who underwent an infrapopliteal intervention
from November 2002 to February 2008. The primary end points evaluated were technical success, limb salvage, primary
patency, and secondary patency. The secondary end points evaluated were 30-day access site (ie, hematoma, pseudoan-
eurysm, and wound infection), intervention site (ie, thrombosis), and systemic (ie, acute renal failure, myocardial
infarction, and mortality) complications. Patency and limb salvage were evaluated using Kaplan-Meier life-table analyses
and compared using Cox regression analysis. P < .05 was considered statistically significant.
Results: The study comprised 85 patients, 89 limbs, and 114 procedures. Age was 72.4  13.1 years, 67% were men, and
follow-up was 245.8  290.8 days. The technical success rate for all procedures was 91%. Limb salvage rates for patients
with critical limb ischemia at 6, 12 and 18 months were 85%  0%, 81%  0%, and 69%  0%, respectively. For the
complete patient cohort, primary patency rates at 6, 12 and 18 months were 68%  6%, 50%  8%, and 37%  9%,
respectively, and secondary patency rates were 81%  5%, 71%  7%, and 63%  8%. Multilevel intervention was
associated with significantly improved secondary patency compared with single-level intervention (P  .045).
Conclusions: Patency and limb salvage rates for endovascular treatment of tibial vessel disease in this study are comparable
with prior reports and with historical surgical controls. Patients who undergo multilevel intervention involving the tibial
vessels exhibit improved secondary patency compared with those who undergo intervention for lesions isolated to the
tibial vessels. This may reflect increased distal disease burden for patients who undergo isolated tibial intervention. The
study data suggest that the presence of multilevel disease should not preclude an attempt at percutaneous revasculariza-
tion. Further study is required before formulating definitive recommendations for the endovascular treatment of tibial
vessel disease. ( J Vasc Surg 2009;49:638-44.)Lower extremity peripheral arterial disease (PAD) is a
major cause of morbidity and mortality that affects approx-
imately 27 million people in North America and Europe.1
Symptoms range from claudication to limb-threatening
critical limb ischemia (CLI), which is exemplified by rest
pain, ulceration, and gangrene. Typically, exercise therapy
and medical optimization are used to treat intermittent
claudication, and surgery is reserved for claudication that is
refractory to conservative management or for CLI.
Surgical approaches are associated with an increased
risk for systemic and local complications due to themultiple
comorbidities that characterize the typical patient with
From the Department of Surgery, New York University School of Medi-
cine,a and Department of Surgery, Division of Vascular Surgery, Mount
Sinai School of Medicine.b
Competition of interest: none.
Presented at the Spring Meeting of the Peripheral Vascular Surgery Society,
San Diego, Calif, Jun 6-7, 2008.
Reprint requests: Peter L. Faries, MD, FACS, Chief, Division of Vascular
Surgery, Mount Sinai School of Medicine, 5 E 98th, Box 1273, New
York, NY 10029-6574 (e-mail: peter.faries@mssm.edu).
0741-5214/$36.00
Copyright © 2009 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2008.10.021
638lower extremity PAD.2 As a consequence, percutaneous
endovascular therapy is increasingly being accepted as an
alternative to surgery for the treatment of PAD. The most
recent TransAtlantic Inter-Society Consensus for the Man-
agement of Peripheral Arterial Disease (TASC-II) guide-
lines delineate specifically those lesions in the aortoiliac and
femoropopliteal regions that are suitable for treatment
using endovascular therapy compared with surgery.2 The
TASC-II recommendations are less well defined for infrap-
opliteal disease due to limited available data on safety and
efficacy.
Infrapopliteal PAD may occur in isolation or simulta-
neously with proximal level disease. Patients withmultilevel
disease are frequently older, have multiple comorbidities,
exhibit increased vascular compromise, and fair worse after
endovascular intervention than patients with isolated dis-
ease of the aortoiliac or femoropopliteal vasculature.3-5 A
comparison has not yet been made between single-level
intervention of the infrapopliteal vasculature and multilevel
intervention involving the infrapopliteal vasculature. This
study sought to assess the overall efficacy of endovascular
intervention in a cohort of patients with disease of the
infrapopliteal vasculature. In addition, this study evaluated
whether the requirement for single-level compared with
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treated for disease of the infrapopliteal vasculature.
METHODS
This study was a retrospective review of a prospectively
maintained database of a consecutive unselected group of
patients who underwent infrapopliteal endovascular treat-
ment for lower extremity PAD from November 2002 to
February 2008. All patients who had undergone a tibial
intervention were included in the study. All procedures
were performed by faculty of the Divisions of Vascular
Surgery from the Mount Sinai School of Medicine and
from the Weill Medical College of Cornell University. The
Ethics Committee and Internal Review Board approved the
study protocol.
Patients. A total of 114 infrapopliteal endovascular
procedures were performed on 89 limbs from 85 patients,
with an average follow-up of 245.8  290.8 days. All
patients who underwent infrapopliteal endovascular inter-
vention during the study period were included in the
analysis.
Preprocedural patency was determined using a combi-
nation of history and physical examination and duplex
ultrasound imaging. Angiography was reserved for patients
who were considered for reintervention. Preprocedural
characteristics included age (72.4  13.1 years; range,
43-92 years), gender (67% men), claudication (23%), CLI
(77%), rest pain (23%), tissue loss (54%), stable angina
(22%), unstable angina (4%), congestive heart failure
(15%), history of coronary artery bypass graft (20%), coro-
nary artery disease (48%), history of myocardial infarction
(21%), cancer (13%), chronic obstructive pulmonary dis-
ease (COPD; 12%), chronic renal insufficiency (17%), cre-
atinine level 1.2 mg/dL (37%), diabetes mellitus (58%),
end-stage renal disease (ESRD; 15%), hyperlipidemia
(54%), hypertension (84%), prior ipsilateral lower extremity
bypass (15%), and tobacco use (51%).
The patients who required reintervention after lower
extremity bypass had failed bypass grafts. Percutaneous
intervention at anastomotic sites was not evaluated in this
study. In addition, no patients had undergone prior endo-
vascular interventions.
Patients were stratified according to whether they had
undergone single-level intervention isolated to the tibial
arteries or multilevel intervention, which was defined as
intervention of the tibial arteries in addition to simulta-
neous intervention of the proximal femoropopliteal vascu-
lature. Staged interventions were not evaluated as multi-
level interventions.When stratifying patients to single-level vs
multilevel intervention, the preprocedural characteristics that
differed significantly were stable angina (single-level, 43% vs
multilevel, 18%; P  .018), creatinine 1.2 mg/dL (single-
level, 41% vs multilevel, 10%; P .002), ESRD (single-level,
29% vsmultilevel, 8%,P .022), andCOPD (single-level, 0%
vs multilevel, 21%; P .007; Table I).
Procedures. Endovascular procedures were performed
in an operating roomangiography suite or in an interventional
radiology suite using a fixed imaging system. All procedureswere performed under local anesthesia using intravenous
sedation. A contralateral femoral up-and-over approach
was used in 63% of interventions, and an ipsilateral ante-
grade approach was used in 37%.
The breakdown of the percutaneous interventions per-
formed was as follows: angioplasty alone, 62%; angioplasty
with stent placement, 28%; laser atherectomy (Spectranet-
ics Corp, Colorado Springs, Colo), 3%; cryoplasty (Boston
Scientific, Natick, Mass), 3%; excisional atherectomy (Fox
Hollow Technologies, Redwood City, Calif), 2%; Angiojet
(Possis Medical Inc, Minneapolis, Minn), 1%; drug-eluting
stent (Cordis, Warren, NJ), 1%; and thrombolysis, 1%.
Stenting was used selectively in patients who exhibited a
flow-limiting dissection or residual stenosis. In the current
study, all patients who received stenting, received stenting
of the tibial arteries. Angiojet and thrombolysis were used
in a case where thrombus was thought to complicate the
stenosis.
Intraprocedural and periprocedural anticoagulation
and antiplatelet therapy with aspirin or clopidogrel, or
both, were administered at the discretion of the investiga-
tor. In general, patients were systemically anticoagulated
intraprocedurally using intravenous unfractionated heparin
with a goal of an activated clotting time of 250 seconds.






(n  60) Pa
Demographics
Age, mean  SD, y 70  13.8 74  12.6 NS
Gender (male), % 59 67 NS
Preprocedural symptoms, %
Claudication 17 25 NS
Critical limb ischemia 83 75 NS
Rest pain 21 18 NS
Tissue loss 62 57 NS
Preprocedural cardiac
history, %
Angina, stable 43 18 .018
Angina, unstable 7 2 NS
Congestive heart failure 29 13 NS
Coronary artery bypass
graft 15 25 NS
Coronary artery disease 50 47 NS
Myocardial infarction 11 23 NS
Preprocedural noncardiac
history, %
Cancer 14 14 NS
COPD 0 21 .007
Creatinine 1.2 mg/dL 41 10 .002
Diabetes 71 61 NS
End-stage renal disease 29 8 .022
Hyperlipidemia 68 47 NS
Hypertension 86 88 NS
Lower limb bypass
(ipsilateral) 14 12 NS
Tobacco use 43 65 NS
COPD, Chronic obstructive pulmonary disease.
aSignificance set at P  .05.Aspirin (Bayer, Leverkusen, Germany) was administered to
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patients undergoing stent placement or atherectomy, clo-
pidogrel (Sanofi-Aventis, Bridgewater, NJ) was adminis-
tered postprocedurally for a minimum of 30 days.
Follow-up. Postprocedural follow-up regimens were
left to the discretion of the investigator. In general, patients
were monitored with regular physical examinations, ankle-
brachial indices/pulse-volume recordings, and arterial du-
plex examinations. Additional imaging was obtained as
clinically indicated.
End points. Primary end points included technical
success, limb salvage, and primary and secondary patency.
Technical success was defined as antegrade flow through
the treated lesion with a residual stenosis of 30% at the
end of the procedure. Limb salvage was defined as resolu-
tion of rest pain or freedom from amputation, including
and proximal to the transmetatarsal level, and this was only
evaluated in patients who presented with CLI. Patients who
presented with claudication were excluded from the analy-
sis of limb salvage.
Primary patency was the duration of follow-up during
which there was an absence of occlusion or restenosis
within the treated segment. Secondary patency was the
duration of follow-up before the requirement for a salvage
intervention for an occlusive lesion. In patients with multi-
level interventions, loss of patency at a single treated level
was considered a treatment failure for the entire limb.
Secondary end points included 30-day access site (ie, he-
matoma, pseudoaneurysm and wound infection), interven-
tion site (i.e. thrombosis), and systemic complications (ie,
acute renal failure, myocardial infarction, and death). The
postprocedural length of stay was also evaluated.
Statistical analysis. All statistical analyses were per-
formed using SPSS 16.0 software (SPSS Inc, Chicago, Ill).
Preprocedural characteristics were reported as a mean 
standard deviation or as a percentage of the total number of
interventions, where appropriate. Discrete variables were
analyzed using the two-tailed Fisher exact test, and contin-
uous variables were analyzed using the two-tailed unpaired
t test. Limb salvage and rates of primary and secondary
patency were evaluated using the Kaplan-Meier life-table
analysis and compared using a Cox regression analysis. P
.05 was considered statistically significant.
RESULTS
Procedural characteristics. The technical success rate
for all procedures was 91%. The results for the 30-day second-
ary end points were access site complications, including hema-
toma (4%), pseudoaneurysm (2%), andwound infection (3%);
intervention site complications, consisting of thrombosis
(2%); and systemic complications, including myocardial in-
farction (1%) and mortality (1%). The average postproce-
dural length of stay was 6.2  9.9 days (range, 1-57 days).
Complication rates were low overall and did not differ
significantly between patients who underwent single-level
compared with multilevel intervention. In addition, com-
plication rates did not differ significantly between patientswho were treated using a contralateral compared with an
antegrade approach.
Limb salvage rates for patients who presented with CLI
were 85%  0% at 6 months, 81%  0% at 12 months, and
69%  0% at 18 months. Primary patency rates for the
complete patient cohort were 68%  6% at 6 months, 50%
 8% at 12 months, and 37%  9% at 18 months, Second-
ary patency was 81%  5% at 6 months, 71%  7% at 12
months, and 63%  8% at 18 months.
All patients who presented with claudication did not
progress to critical limb ischemia. As a corollary, no claudi-
cant patients required reintervention. A total of 26 initially
treated tibial vessels required reintervention to attain sec-
ondary patency. The lesion location distribution was ante-
rior tibial in 38%, peroneal in 31%, tibioperoneal trunk in
23%, and posterior tibial in 8%.
Log-rank analysis demonstrated that single-level and
multilevel intervention differed significantly with regards to
secondary patency (Table II). Multilevel intervention was
associated with significantly improved secondary patency
rates compared with single-level intervention (P  .045;
Figs 1-3). Stable angina, creatinine 1.2 mg/dL, and
ESRD were more prevalent in patients who underwent
single-level intervention. COPD was more prevalent in
patients who underwent multilevel intervention (Table I).
The comorbidities of stable angina, elevated creatinine,
ESRD, and COPD did not correlate significantly with
primary or secondary patency or limb salvage in patients
treated using single-level vs multilevel interventions.
DISCUSSION
Patients with lower extremity PAD exhibit significant
variability in clinical presentation and in the localization of
disease within the lower extremity vasculature. Patients may
present with symptoms that range from intermittent clau-
dication to rest pain or to tissue loss. The pattern of
localization of vascular disease that results in clinically sig-
Table II. Log rank analysis of limb salvage rates for
patients with critical limb ischemia and of patency rates






PaMean  SD, % Mean  SD, %
Limb salvage
6 months 83  7 88  5 NS
12 months 75  10 84  6 NS
18 months 67  12 63  19 NS
Primary patency
6 months 62  10 71  8 NS
12 months 34  12 58  9 NS
18 months 27  11 48  12 NS
Secondary patency
6 months 65  10 89  5 .045
12 months 52  12 85  6 .045
18 months 46  12 57  18 .045
aSignificance set at P  .05.nificant sequelae ranges from a lesion that is isolated to a
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present simultaneously at multiple levels. This study evalu-
ated patients who were treated for disease of the infrapop-
liteal vasculature, which presented as single-level or multi-
level disease.
The risk factors that characterize disease of the infrapop-
liteal vasculature are similar to those that characterize aor-
toiliac and femoropopliteal disease: advanced age, smoking,
diabetes, hypertension, hyperlipidemia, male gender, prior
myocardial infarction, and heart failure.3,6-8 In particular,
diabetes affects 63% to 91% of patients undergoing treat-
ment for infrapopliteal PAD.9
Revascularization therapy may consist of endovascular
therapy or surgical bypass. In general, patients treated for
severe infrapopliteal disease exhibit diminished long-term
patency for both surgical bypass and endovascular interven-
tion with patients with disease isolated to the more proxi-
mal vasculature.10,11
Initially, the endovascular treatment of lower extremity
Fig 1. Limb salvage rates for patients with critical limb ischemia
stratified by single-level vs multilevel intervention.
Fig 2. Primary patency rates for the complete patient cohort
stratified by single-level versus multilevel intervention.PAD involving the infrapopliteal vasculature was limitedbefore the development of low-profile balloon catheters
and steerable guidewires.12 As a consequence, early experi-
ence with the endovascular treatment of infrapopliteal PAD
generated poor immediate and long-term outcomes.13,14
Some of the potential factors that contributed to the initially
poor outcomes included long-segment disease, occluded
lesions, compromise to outflow vessels, and the potential
compromise to future surgical bypass. Advances in endo-
vascular technique and the use of adjunctive modalities
have generated improved outcomes for the endovascular
management of lower extremity PAD.15
The updated TASC-II guidelines state that for the
endovascular treatment of infrapopliteal disease, angio-
plasty may be indicated for limb salvage but should not be
used for the treatment of intermittent claudication.2 The
guidelines further state that there is evidence for the treat-
ment of short tibial artery stenoses if the patient is simulta-
neously undergoing treatment for femoropopliteal disease.
In addition, the treatment of tibial artery occlusions should
be reserved for cases where in-line flow to the pedal vascu-
lature can be re-established. In the current study, the
treatment of patients who presented with claudication was
performed infrequently and only if the disease limited per-
fusion to the leg.
Currently, no level I data evaluate the treatment of
infrapopliteal PAD using endovascular therapy. In general,
technical success and clinical success rates approach 90%
and 70%, respectively.2 With regards to angioplasty as the
treatment modality, a retrospective review of 67 patients
with CLI treated using infrapopliteal angioplasty demon-
strated a technical success rate of 86% and a 3-year limb
salvage rate of 94%.16 Another review of 46 patients with
CLI treated using infrapopliteal angioplasty demonstrated
a technical success rate of 80% and a 2-year limb salvage rate
Fig 3. Secondary patency rates for the complete patient cohort
stratified by single-level vs multilevel intervention. Cox regression
analysis demonstrated that multilevel intervention was associated
with significantly improved secondary patency rates as compared to
single-level intervention (P  .045; Table II).of 87%.17 A review that evaluated the treatment of CLI
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demonstrated 1-year primary, secondary, and clinical pa-
tency rates of 46%, 55%, and 63%, respectively. Limb sal-
vage rates at 1 and 2 years were 87%.18
Bosiers et al19 performed one of the largest retrospec-
tive reviews in patients treated for CLI using infrapopliteal
endovascular therapy. A total of 681 below knee interven-
tions were performed in 443 patients with CLI. Patients
were treated using angioplasty alone, angioplasty with
stenting, or laser atherectomy (Spectranetics Corp, Colo-
rado Springs, Colo). Primary patency rates were, respec-
tively, 85.2% and 74.2% at 6 months and 1 year, and limb
salvage rates were 97.0% and 96.6%. Subset analyses com-
paring the different treatment modalities did not demon-
strate any statistically significant differences. The results of
the retrospective reviews evaluating infrapopliteal endovas-
cular therapy compare favorably with historical surgical
controls. Level I evidence is still required to determine
definitive management.
Disease of the infrapopliteal vasculature is a likely indi-
cator of significant atherosclerotic burden. As a conse-
quence, infrapopliteal PAD is frequently accompanied by
disease of the proximal lower extremity vasculature. The
endovascular treatment of multilevel disease is thought to
result in worse outcomes compared with the treatment of
single-level disease of the femoropopliteal or aortoiliac
vasculature, because each lesion has its own failure rate that
results in an additive effect.2 In addition, patients with
multilevel disease are frequently older, have more comor-
bidities, and have lower baseline ankle-brachial indices than
patients with single-level disease.3-5 A comparison has not
yet been made between single-level interventions of the
infrapopliteal vasculature and multilevel interventions in-
volving the infrapopliteal vasculature.
This study evaluated patients with lower extremity
PAD who underwent endovascular treatment of the infrap-
opliteal vasculature in addition to treatment of the proximal
vasculature, as indicated. The technical success rate of the
entire patient cohort (91%) was comparable with other
retrospective reviews, and the primary patency and second-
ary patency and limb salvage rates were also comparable
with other reports. Log-rank analysis demonstrated that
multilevel intervention was associated with significantly
improved secondary patency compared with single-level
intervention (P  .045). Stable angina, creatinine 1.2
mg/dL, and ESRD were more prevalent in patients who
underwent single-level intervention, and COPD was more
prevalent in patients who underwent multilevel interven-
tion.
One explanation for the study results is that patients
with single-level disease may exhibit locally increased ath-
erosclerotic burden compared with patients with multilevel
disease. This may have resulted in the increased frequency
of secondary interventions that were performed in patients
with single-level infrapopliteal disease. Diabetes was not
found to be more prevalent in patients with single-level
disease, and this is a significant risk factor for PAD that
involves the infrapopliteal vasculature.9A limitation of this study is that consensus guidelines
currently do not exist for classifying tibial lesions. There-
fore, preoperative lesion characteristics could not be com-
pared between patients treated using single-level compared
with multilevel intervention.
In addition, preprocedural patient characteristics, co-
morbidities, and indications for surgery were not equiva-
lent between the two patient cohorts due to the absence of
randomization. Specifically, there was a nonsignificant
trend towards an increased incidence of CLI in patients
who underwent single-level infrapopliteal intervention.
Nevertheless, no significant differences were noted that
differentiated the groups in such a way that selection of
patients could be improved to obtain improved outcomes.
This was a retrospective review where preprocedural,
intraprocedural, and postprocedural parameters were left to
the discretion of the investigator. The postprocedural stay
was significant in duration and exhibited significant vari-
ability because patients frequently required hospitalization
for wound care or for the treatment of other comorbidities.
Data for the overall technical success, limb salvage, and
patency were frequently comparable with prior studies;
however, some of the reports cited described better out-
comes. One possible explanation is that a range of factors
impact limb salvage, not just patency. In addition, the
definitions for limb salvage and patency are not uniform
across the various reports. For example, certain reports
included patients treated for claudication in the statistics for
limb salvage. In this report, limb salvage was evaluated only
for patients who presented with CLI.
Furthermore, the study was not powered to evaluate
the difference in outcomes between patients treated for
single-level vs multilevel disease. Therefore, nonsignificant
trends were noted that demonstrated improved outcomes
for the treatment of multilevel compared with single-level
disease with regards to primary patency and limb salvage.
However, secondary patency was the only outcome evalu-
ated that was found to be significantly different between the
two patient cohorts.
CONCLUSIONS
The data in this study demonstrate that the technical
success, limb salvage, and primary and secondary patency
rates of the entire patient cohort are comparable with prior
reports evaluating the endovascular treatment of infrapop-
liteal PAD and with historical surgical controls. In addition,
patients who undergo a multilevel intervention involving
the tibial vessels exhibit improved secondary patency com-
pared with those who undergo intervention for lesions
isolated to the tibial vessels. This may reflect increased distal
disease burden for those patients who undergo isolated
tibial intervention. Further study is required before formu-
lating definitive recommendations for the endovascular
treatment of infrapopliteal disease and before the use of
adjunctive modalities to mitigate the potential for failure
associated with endovascular therapy.
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 3 Sadek et al 643AUTHOR CONTRIBUTIONS
Conception and design: MS, SE, RL, MM, PF
Analysis and interpretation: MS, SE, IT, PF
Data collection: MS, SE, IT, RL, PF
Writing the article: MS, SE
Critical revision of the article: MS, SE, IT, RL, MM, PF
Final approval of the article: MS, SE, IT, RL, MM, PF
Statistical analysis: MS, SE, IT
Obtained funding: MM, PF
Overall responsibility: PF
REFERENCES
1. Jemal A, Ward E, Hao Y, ThunM. Trends in the leading causes of death
in the United States, 1970-2002. JAMA 2005;94:1255-9.
2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes
FG. TASC II Working Group. Inter-Society Consensus for the Man-
agement of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;
45(suppl S):S5-67.
3. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, et al.
Mortality over a period of 10 years in patients with peripheral arterial
disease. N Engl J Med 1992;326:381-6.
4. Vogt MT, Wolfson SK, Kuller LH. Segmental arterial disease in the
lower extremities: correlates of disease and relationship to mortality.
J Clin Epidemiol 1993;46:1267-76.
5. Conte MS, Belkin M, Upchurch GR, Mannick JA, Whittemore AD,
Donaldson MC. Impact of increasing comorbidity on infrainguinal
reconstruction: a 20-year perspective. Ann Surg 2001;233:445-52.
6. Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent
claudication. A risk profile from The Framingham Heart Study. Circu-
lation 1997;96:44-9.
7. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter
LM, et al. Hyperhomocysteinemia is associated with an increased risk of
cardiovascular disease, especially in non-insulin-dependent diabetes
mellitus: a population-based study. Arterioscler Thromb Vasc Biol
1998;18:133-8.8. Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preex-
isting cardiovascular conditions and long-term prognosis after initial
you had ballooned?myocardial infarction: the Framingham Study. Am Heart J 1993;125:
863-72.
9. Dormandy JA, Rutherford RB. Management of peripheral arterial dis-
ease (PAD). TASC Working Group. TransAtlantic Inter-Society Con-
sensus (TASC). J Vasc Surg 2000;31:S1-S296.
10. DeRubertis BG, Faries PL, McKinsey JF, Chaer RA, Pierce M, Kar-
wowski J, et al. Shifting paradigms in the treatment of lower extremity
vascular disease: a report of 1000 percutaneous interventions. Ann Surg
2007;246:415-22; discussion 422-4.
11. Schweiger H, Klein P, Lang W. Tibial bypass grafting for limb salvage
with ringed polytetrafluoroethylene prostheses: results of primary and
secondary procedures. J Vasc Surg 1993;18:867-74.
12. Schwarten DE, Cutcliff WB. Arterial occlusive disease below the
knee: treatment with percutaneous transluminal angioplasty per-
formed with low-profile catheters and steerable guide wires. Radiol-
ogy 1988;169:71-4.
13. Treiman GS, Treiman RL, Ichikawa L, Van Allan R. Should percutane-
ous transluminal angioplasty be recommended for treatment of infra-
geniculate popliteal artery or tibioperoneal trunk stenosis? J Vasc Surg
1995;22:457-63.
14. Parsons RE, Suggs WD, Lee JJ, Sanchez LA, Lyon RT, Veith FJ.
Percutaneous transluminal angioplasty for the treatment of limb threat-
ening ischemia: do the results justify an attempt before bypass grafting?
J Vasc Surg 1998;28:1066-71.
15. Rogers JH, Laird JR. Overview of new technologies for lower extremity
revascularization. Circulation 2007;116:2072-85.
16. Ingle H, Nasim A, Bolia A, Fishwick G, Naylor R, Bell PR, et al.
Subintimal angioplasty of isolated infragenicular vessels in lower limb
ischemia: long-term results. J Endovasc Ther 2002;9:411-6.
17. Markose G, Bolia A. Subintimal angioplasty in the management of
lower limb ischaemia. Cardiovasc Surg 2006;47:399-406.
18. Vraux H, Bertoncello N. Subintimal angioplasty of tibial vessel occlu-
sions in critical limb ischaemia: a good opportunity? Eur J Vasc Endo-
vasc Surg 2006;32:663-7.
19. Bosiers M, Hart JP, Deloose K, Verbist J, Peeters P. Endovascular
therapy as the primary approach for limb salvage in patients with critical
limb ischemia: experience with 443 infrapopliteal procedures. Vascular
2006;14:63-9.Submitted Jun 5, 2008; accepted Oct 10, 2008.DISCUSSION
Dr Colleen Johnson (Springfield, Ill). I have two questions
for you. Can you better define multilevel disease and whether that
was a predominance of aortoiliac disease or femoropopliteal dis-
ease, as those behave a little differently postintervention. Secondly,
in themanuscript youmention that your length of hospital stay was
6.2 days, plus or minus 9 days. Most of us would consider percu-
taneous interventions to be a 1?day procedure, and I am a little
curious as to what the protocol or treatment paradigms were that
surrounded those longer hospital stays.
Dr Mikel Sadek. In this study, the levels of vascular disease
were divided into three categories: (1) the tibial or infrapopliteal
vasculature, (2) the femoropopliteal vasculature, and (3) the aor-
toiliac vasculature. Single-level disease referred specifically to iso-
lated disease of the infrapopliteal vasculature. Multilevel disease
involved the infrapopliteal vasculature, as well as at least one
additional level.
With regards to the length of hospital stay, patients were
included in this study who were not in the hospital initially for
treatment of their lower extremity peripheral arterial disease.
Therefore, other medical issues frequently kept patients in the
hospital beyond the typical postprocedural course for recovery.
Dr Anil Hingorani (Brooklyn, NY). I just wanted to ask
about your patency rates in terms of how did you obtain patency
rates? Did you just do duplexes of all the infrapopliteal arteries thatDr Sadek. Patency rates were obtained postprocedurally us-
ing a combination of ABI/PVR [ankle-brachial index/pulse vol-
ume recording] and duplex studies.
Dr Hingorani. So do you routinely get duplex studies of the
infrapopliteal vessels on these types of patients?
Dr Sadek. Postprocedural follow?up was left to the discretion
of the investigator. That said, the majority of investigators rou-
tinely obtain ABI/PVR and duplex studies postprocedurally.
Dr Victor Bernhard (Chicago, Ill). I am somewhat confused
as to why the multilevel patients did better than the single?level
patients, unless I missed your stratification of how much tibial
disease was present in one group vs the other. Maybe you could
clarify that.
Dr Sadek. The severity of tibial disease may be the reason why
patients who underwent multilevel intervention exhibited im-
proved outcomes as compared to patients who underwent single-
level intervention. Additional analysis might clarify whether in-
creased distal disease burden affected outcomes.
Dr Bernhard. In other words, you haven’t stratified them
according to the degree of tibial disease?
Dr Sadek.Correct.
Dr Hasan Dosluoglu (Buffalo, NY). The limb salvage was
somewhat lower at 18 months, or 68%, if I got it correctly. Was
limb salvage rate different between diabetics and nondiabetics in
this series? Ironically the patients with one?level disease that you
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ones who did worse. So does that really mean that when you have
a somewhat acceptable looking SFA [superficial femoral artery],
little ragged and with diffuse disease, maybe, ironically, should be
the ones that we should more aggressively consider bypasses,
because that one?level correction of the most significant stenosis
may not be enough. Maybe that is what your study is actually
telling us. What do you think?
Dr Sadek.With regards to your first question and diabetes, we
did not note a difference in limb salvage between diabetics and
non-diabetics. And with regards to your second question, I think
you make a valid point.
Dr Peter Schubart (San Jose, Calif). I wanted to commend
you on your series and to note that you did have 10%more diabetic
patients in the tibial vessel disease, which I think would tend to add
to the trend of failure. I wondered whether, in looking at your
patency data, whether in the multilevel disease you discriminated
between failure in the proximal segment and failure in the tibials?
In other words, was the tibial failure equivalent between the two
groups?Dr Sadek. For multilevel interventions, whenever there was a
failure anywhere along the vascular tree that required reinterven-
tion, that affected the patency.
Dr Schubart. It might be interesting to analyze the data by
infrapopliteal vs above the knee in terms of trying to see if you are
treating apples and apples.
Dr Sadek. Absolutely. You make an excellent suggestion.
Dr Manju Kalra (Rochester, Minn). I too am intrigued by
your results of multilevel vs single-level treatment. In patients with
multilevel treatment, did you set out primarily to treat the femo-
ropopliteal segment or the tibial segment? It would also be inter-
esting to know the extent of disease and TASC [TransAtlantic
InterSociety Consensus] classification of the femoropopliteal seg-
ments treated in order to assess their relative significance and
contribution to clinical improvement following intervention.
Dr Sadek. With regards to multilevel disease, which came
first, the chicken or the egg? This was a retrospective review of a
prospectively maintained database; therefore, I cannot make a
comment at this time regarding the intention for treatment. And
with regards to TASC classification for the femoropopliteal lesions,
that is an excellent suggestion for improving the manuscript.
